Wellington Management

SiteOne Therapeutics is a San Francisco-based company developing innovative therapeutics and diagnostics for acute and chronic pain. Their lead candidates are selective inhibitors of the Naᵥ1.7 ion channel, aiming to treat pain safely and effectively without relying on NSAIDs or opioids.

Databricks offers a unified data analytics platform that simplifies data integration, enables real-time experimentation, and facilitates robust deployment of production applications for developers and data scientists. Serving diverse industries worldwide, Databricks' platform supports collaborative data science, machine learning workflows, and integrates with various cloud services.

Archer develops and operates all-electric vertical takeoff and landing aircraft, aiming to enhance urban mobility sustainably. Its four-passenger aircraft can travel up to 60 miles at speeds reaching 150 mph with minimal noise.

Founded in 2018, Crisp is a Brooklyn-based company that provides demand forecasting software for the food industry. It connects consumer packaged goods (CPG) companies to real-time point-of-sale and inventory data from over 40 retailers and distributors, delivering store-level insights through business intelligence tools.

Abnormal Security Corporation is a San Francisco-based company that specializes in cloud-based email security solutions for Microsoft Office 365 and G Suite. Founded in 2018, the company provides a comprehensive platform designed to protect enterprises from targeted email attacks. Utilizing a data science approach, Abnormal Security offers features such as inbound email protection, detection of email account compromises, and response capabilities. Its technology includes Abnormal Behavior Technology, which models identities of both employees and external senders, profiles relationships, and analyzes email content to prevent threats like credential phishing, internal phishing, employee impersonation, and invoice fraud. The company primarily serves industries including financial services, healthcare, and oil, gas, and utilities, aiming to mitigate risks related to account takeovers and financial losses.

MBX Biosciences is a biotechnology company focused on developing therapies for endocrine and metabolic disorders, emphasizing rare endocrine diseases with limited treatment options. It pursues discovery, development, and commercialization of first-in-class peptide therapeutics that modulate glandular hormone signaling. MBX has developed a proprietary Precision Endocrine Peptide platform to engineer peptides with extended time-action profiles and consistent drug exposure, aiming to overcome limitations of traditional peptide therapies and improve disease management. Based in Carmel, Indiana, the company advances novel peptide programs through clinical development to address unmet medical needs in endocrine and metabolic disorders.

Founded in 2020 and headquartered in Boston, Massachusetts, Scorpion Therapeutics is a clinical-stage biotechnology company specializing in precision oncology. It develops targeted small-molecule drugs to treat cancer by focusing on three areas: therapies against known oncogenes, agents for currently undruggable targets, and drugs for new targets.

Element Biosciences develops innovative genetic analysis tools for research and diagnostic markets. Founded in 2017, the company specializes in a disruptive DNA sequencing technology that offers high-quality data, workflow flexibility, and affordable access to next-generation sequencing.

Disc Medicine is a clinical-stage biopharmaceutical company focused on developing innovative treatments for patients with severe hematologic disorders. Its pipeline includes therapies targeting erythropoietic porphyrias, Diamond-Blackfan Anemia, anemia of myelofibrosis and chronic kidney disease, as well as polycythemia vera.

Scale AI develops a platform that provides training and validation data for artificial intelligence applications. Its products include advanced annotation tools for images, videos, text, documents, and 3D sensor data, serving sectors such as autonomous vehicles, retail, conversational AI, robotics, AR/VR, and document processing.

Wiz, Inc. is a cybersecurity company founded in 2020, with headquarters in Palo Alto, California, and an additional office in Tel Aviv, Israel. The company specializes in cloud security, providing enterprises with a platform that enables them to identify security issues within their public cloud infrastructure. Wiz's innovative solution offers a comprehensive, cloud-native visibility tool that analyzes the entire cloud environment, delivering a 360-degree view of security risks across various platforms, including clouds, containers, and workloads. The platform utilizes actionable, graph-based analysis to facilitate in-depth risk assessment and root cause analysis without the need for agents, allowing organizations to enhance their security posture effectively.

Zenas BioPharma is a clinical-stage biopharmaceutical company focused on developing immune-based therapies for autoimmune and immune-mediated diseases. Based in Florida, United States, the company advances biologic programs and aims to modulate B cell–driven pathology. Its lead product candidate, obexelimab, is a bifunctional monoclonal antibody designed to bind both CD19 and FcγRIIb on B cells, thereby inhibiting harmful immune activity without depleting B cells.

Asher Biotherapeutics, Inc. is a biotechnology company based in South San Francisco, California, founded in 2019. The company specializes in the development of immunotherapy drugs aimed at effectively treating cancer. Its innovative therapies are designed to enhance the immune system's ability to target and eliminate cancer cells while minimizing side effects. This focus allows healthcare providers to deliver effective treatments to patients in a shorter timeframe, aiming to improve overall outcomes in cancer care.

Avidity Biosciences is a biopharmaceutical company developing antibody oligonucleotide conjugates to enable tissue-selective delivery and precision RNA therapies for serious diseases. Its AOC platform combines monoclonal antibody tissue targeting with oligonucleotide therapies to access previously undruggable tissues and genetic drivers. The lead candidate, AOC 1001, targets myotonic dystrophy type 1, and its muscle programs address muscle atrophy, Duchenne muscular dystrophy, facioscapulohumeral muscular dystrophy, and Pompe disease. The pipeline also includes immune and other cell-type programs, including Del-zota for DMD, Del-desiran for DM1, and Del-brax for FSHD. Avidity is based in La Jolla, California.

Quince, LLC, established in 2016 and headquartered in San Francisco, California, is a retailer specializing in affordable luxury apparel, accessories, and home goods. The company offers a wide range of products for men and women, including jewelry, clothing, and home textiles, all sourced directly from manufacturers using a just-in-time production model. This approach enables Quince to provide high-quality items at competitive prices while minimizing waste.

Avalyn Pharma is a biopharmaceutical company focused on developing therapies for severe respiratory diseases, notably idiopathic pulmonary fibrosis (IPF). Established in 2011, the company is headquartered in Seattle, Washington.

Trove is a technology company offering AI-powered tools for professional networking, email management, and a resale platform for brands and retailers. Its mobile email product uses artificial intelligence to reduce inbox overload, surface relationship insights, provide smart notifications, and snooze messages, integrating with existing email services and supporting iOS and Android. In parallel, Trove operates a resale platform that helps brands launch, manage, and scale resale programs, with storefront design, photography, authentication, cleaning and repair, returns processing, non-new inventory management, site building, Shopify integration, and analytics, plus in-store and digital trade-ins and peer-to-peer features. By combining AI-driven relationship mapping with a scalable resale ecosystem, Trove enables brands to deepen engagement, optimize profit, and reach new customers, and holds certification as a B Corporation for its sustainability-focused approach.

Alkeus Pharmaceuticals is a clinical-stage biopharmaceutical company based in Boston that specializes in developing treatments for serious ophthalmic conditions. The company's primary focus is on addressing untreatable diseases of the eye, with its lead drug candidate being an orally delivered compound aimed at treating Stargardt disease and age-related macular degeneration. Through its innovative approach, Alkeus aims to empower medical professionals to manage symptoms of irreversible vision loss at an earlier stage in affected patients.

Boundless Bio develops innovative cancer therapeutics focused on understanding and treating previously untreatable cancers. It specializes in targeting extrachromosomal DNA (ecDNA) biology, a key driver of aggressive cancers.

Quince, LLC, established in 2016 and headquartered in San Francisco, California, is a retailer specializing in affordable luxury apparel, accessories, and home goods. The company offers a wide range of products for men and women, including jewelry, clothing, and home textiles, all sourced directly from manufacturers using a just-in-time production model. This approach enables Quince to provide high-quality items at competitive prices while minimizing waste.

HeartFlow specializes in precision heart care, offering a non-invasive solution for diagnosing coronary artery disease. Its proprietary HeartFlow FFRCT Analysis uses artificial intelligence to create a personalized 3D model of the heart, enabling clinicians to evaluate blood flow and determine optimal treatment. Commercially available in the United States, UK, Canada, Europe, and Japan.

Chroma Medicine is a genomic medicine company founded in 2021 and based in Cambridge, Massachusetts, specializing in epigenetic editing. The company is pioneering a new class of genomic therapies aimed at revolutionizing the treatment of genetically driven diseases. By utilizing epigenetics, which is the natural mechanism for gene regulation, Chroma Medicine develops programmable epigenetic editors that target specific genes and modulate chromatin conformation. This innovative approach enables healthcare providers to achieve precise control of gene expression, offering a promising therapeutic option for conditions linked to genetic anomalies.

Dataiku develops a centralized data platform that empowers businesses to navigate their data journey, from analytics at scale to enterprise AI. Its platform fosters collaboration among data experts and explorers, providing a repository of best practices, streamlined machine learning deployment, and a controlled environment. Established in 2013, Dataiku is headquartered in New York with offices in Paris and London.

Apogee Therapeutics is a biotechnology company focused on developing therapies for immunological and inflammatory disorders. Based in San Francisco and founded in 2022, it aims to advance novel biologics to address patients’ unmet needs. The company pursues differentiated antibody programs targeting well-established mechanisms implicated in atopic dermatitis, chronic obstructive pulmonary disease, and related inflammatory and immunology indications, supported by antibody engineering to optimize half-life and other properties.

MBX Biosciences is a biotechnology company focused on developing therapies for endocrine and metabolic disorders, emphasizing rare endocrine diseases with limited treatment options. It pursues discovery, development, and commercialization of first-in-class peptide therapeutics that modulate glandular hormone signaling. MBX has developed a proprietary Precision Endocrine Peptide platform to engineer peptides with extended time-action profiles and consistent drug exposure, aiming to overcome limitations of traditional peptide therapies and improve disease management. Based in Carmel, Indiana, the company advances novel peptide programs through clinical development to address unmet medical needs in endocrine and metabolic disorders.

Zenas BioPharma is a clinical-stage biopharmaceutical company focused on developing immune-based therapies for autoimmune and immune-mediated diseases. Based in Florida, United States, the company advances biologic programs and aims to modulate B cell–driven pathology. Its lead product candidate, obexelimab, is a bifunctional monoclonal antibody designed to bind both CD19 and FcγRIIb on B cells, thereby inhibiting harmful immune activity without depleting B cells.

RayzeBio, Inc. is a biotechnology company based in San Diego, California, founded in 2020. The company specializes in developing tumor-targeted small molecule medicines that leverage radioisotopes to improve cancer treatment outcomes. RayzeBio focuses on creating innovative radiopharmaceuticals, particularly utilizing alpha-emitting radioisotopes like Actinium-225, to target solid tumors effectively. With a robust pipeline of drug candidates, RayzeBio is committed to addressing significant market opportunities in oncology through late-stage clinical programs, development initiatives, and discovery efforts. The company's mission is to provide effective therapeutic solutions aimed at defeating cancer.

Flavrs is an online food discovery platform founded in 2020, headquartered in San Francisco. It combines premium food content with commerce, allowing users to watch recipe tutorials from renowned chefs and shop for ingredients via Instacart integration.

Founded in 2009, SeatGeek operates a mobile ticketing marketplace and search engine for live sports, concerts, and theater events. It aggregates ticket listings from various sources, offering users a 'Deal Score' metric to assess ticket value. The platform also provides event discovery tools based on user preferences. SeatGeek is headquartered in New York with additional offices globally.

Meati Foods produces and sells fungi-based meat alternatives. Founded in 2016, the company uses proprietary clean technologies to create nutrient-dense, plant-based products that are free from common allergens.

FalconX is a cryptocurrency brokerage and digital asset trading platform founded in 2018. It provides trading solutions that give institutions reliable execution and cost efficiency in cryptocurrency markets. The platform uses data science to eliminate slippage and hidden fees, along with blockchain technology and machine learning to route mid-to-large size trades across multiple liquidity sources. FalconX offers trading, credit, and clearing services to hedge funds, proprietary trading firms, and other institutional clients seeking transparent, scalable digital asset execution.

Arcadia, Inc. is a technology company based in Washington, D.C., founded in 2014, that focuses on providing access to clean energy solutions. Through its platform, Arc, the company connects subscribers to renewable energy sources such as wind farms and community solar projects. By enabling users to manage their accounts, track energy usage, and participate in clean energy initiatives, Arcadia aims to democratize access to renewable energy and combat the fossil fuel monopoly. The platform aggregates energy data from over 125 utilities, representing more than 80% of U.S. electric utility accounts, thus facilitating a significant shift toward sustainable energy practices. Additionally, Arcadia's community solar program addresses energy injustice while promoting economic growth, contributing over five Terawatt-hours of energy demand from residential and commercial users.

Omada Health is a digital healthcare company that offers personalized programs to manage chronic conditions such as prediabetes, diabetes, hypertension, musculoskeletal issues, and behavioral health. It combines professional coaching, connected devices, real-time data, and personalized feedback to deliver clinically meaningful results.

Somatus, Inc. is a healthcare company focused on providing specialized kidney care services aimed at delaying or preventing the progression of chronic kidney disease. Founded in 2016 and headquartered in McLean, Virginia, Somatus collaborates with health plans, health systems, nephrology, and primary care groups to deliver integrated care for patients with or at risk of kidney disease. Its comprehensive services include home hemodialysis, peritoneal dialysis, in-center hemodialysis, kidney transplant, and conservative care. By utilizing vertically integrated clinical services and technology, Somatus seeks to improve patient outcomes, enhance care coordination, and promote the use of home dialysis modalities while increasing the rates of kidney transplantation. The company's mission is to ensure that patients can access the care they need to manage kidney disease effectively.

Synthego is a biotechnology company specializing in genome engineering. It offers integrated hardware, software, bioinformatics, chemistries, and molecular biology platforms to advance basic research and therapeutic development. Its products include engineered cells, CRISPR kits, and bioinformatics tools for gene knockout, target validation, and disease modeling. Synthego serves scientists globally, with sales through distributors in multiple countries and online.

CodeSee is a developer of cloud-based data visualization software aimed at enhancing code comprehension for developers and development teams. Founded in 2019 and based in San Francisco, California, the company provides tools that facilitate a continuous understanding of the codebase throughout the development process. Its software enables users to visualize how various elements of code and functionality are interconnected, thereby improving the overall workflow and efficiency of software development.

Founded in 2015, Dave is a fintech company based in Los Angeles, California. It operates a mobile application that provides users with banking services, including overdraft protection, early access to paychecks, and credit building tools. The app aims to improve financial wellness by offering transparent, fee-free banking and has grown to serve over 12 million members since its inception.

Anchorage Digital is a regulated crypto platform that provides institutions with integrated custody, trading, staking, governance, and regulatory-compliance infrastructure for digital asset programs. Founded in 2017 and headquartered in San Francisco, it serves institutional clients globally with a secure, compliant framework and services designed to simplify oversight and asset management.

Course Hero operates as an online learning platform dedicated to providing study resources for students and educators. Founded in 2006 and based in Redwood City, California, the company offers a range of materials including lecture notes, study guides, textbook help, practice problems, exams, and video lectures from universities across the United States and internationally. Course Hero's platform is subscription-based and includes an educator platform for distributing materials and publishing content. Additionally, it features a flashcards application and access to expert tutors who assist students with their queries. The company was previously known as TheCollegeFreeway.

Chroma Medicine is a genomic medicine company founded in 2021 and based in Cambridge, Massachusetts, specializing in epigenetic editing. The company is pioneering a new class of genomic therapies aimed at revolutionizing the treatment of genetically driven diseases. By utilizing epigenetics, which is the natural mechanism for gene regulation, Chroma Medicine develops programmable epigenetic editors that target specific genes and modulate chromatin conformation. This innovative approach enables healthcare providers to achieve precise control of gene expression, offering a promising therapeutic option for conditions linked to genetic anomalies.

Faire is a two-sided marketplace connecting local retail stores with unique wholesale merchandise from brands and makers. It offers retailers tools for data insights, financial terms, and logistics support to compete with larger competitors. Faire's platform simplifies wholesale buying and selling processes, offering net 60 payment terms and free returns.

BetterUp Inc. is a leadership development company that offers an innovative online platform aimed at enhancing the personal and professional growth of individuals and organizations. Founded in 2013 and headquartered in San Francisco, BetterUp specializes in virtual coaching, providing users with personalized guidance through one-on-one sessions with a network of over 3,000 coaches available in 46 languages across more than 90 countries. The platform focuses on fostering mental fitness, career and leadership development, and social connection, thereby enabling employees to develop new behaviors and skills that promote high performance in a rapidly changing work environment. With a client base that includes prominent organizations such as NASA, Google, and Hilton, BetterUp has established itself as a leader in the field of mental health and coaching. The company is supported by a distinguished Science Board composed of experts in positive psychology and human performance, further enhancing its credibility and impact in the industry.

Ventyx Biosciences is a clinical-stage biopharmaceutical company focused on developing novel therapies for patients with inflammatory diseases and autoimmune disorders. Its pipeline includes VTX958, an oral, selective TYK2 inhibitor in Phase 1 trials for various autoimmune diseases.

Archaea Energy is a developer of renewable natural gas (RNG) in the United States. Founded in 2018 in Canonsburg, Pennsylvania, the company focuses on capturing waste emissions and converting them into low-carbon fuel. It builds, operates, and maintains RNG facilities to supply fuel for industries difficult to electrify. Archaea Energy aims to redefine the RNG industry through a disciplined, sustainable project-development approach and by selling RNG under long-term, fixed-price contracts to creditworthy partners. The business emphasizes cost-efficient manufacturing and scalable deployment of RNG projects to support decarbonization efforts.

Arcadia, Inc. is a technology company based in Washington, D.C., founded in 2014, that focuses on providing access to clean energy solutions. Through its platform, Arc, the company connects subscribers to renewable energy sources such as wind farms and community solar projects. By enabling users to manage their accounts, track energy usage, and participate in clean energy initiatives, Arcadia aims to democratize access to renewable energy and combat the fossil fuel monopoly. The platform aggregates energy data from over 125 utilities, representing more than 80% of U.S. electric utility accounts, thus facilitating a significant shift toward sustainable energy practices. Additionally, Arcadia's community solar program addresses energy injustice while promoting economic growth, contributing over five Terawatt-hours of energy demand from residential and commercial users.

SpotOn is a technology company founded in 2017 by Doron Friedman, Matt Hyman, and Zach Hyman, headquartered in San Francisco, California. The company specializes in providing innovative software and payment solutions tailored for small and midsize businesses. SpotOn offers a comprehensive, cloud-based platform that includes tools for payments, point-of-sale systems, marketing, website development, online ordering, appointments, eCommerce, digital loyalty, and review management. By integrating these services, SpotOn aims to enhance operational efficiency and customer engagement for its clients. The company's mission is to empower businesses by delivering high-quality solutions at fair prices, supported by personalized local service.

Asher Biotherapeutics, Inc. is a biotechnology company based in South San Francisco, California, founded in 2019. The company specializes in the development of immunotherapy drugs aimed at effectively treating cancer. Its innovative therapies are designed to enhance the immune system's ability to target and eliminate cancer cells while minimizing side effects. This focus allows healthcare providers to deliver effective treatments to patients in a shorter timeframe, aiming to improve overall outcomes in cancer care.

Trove is a technology company offering AI-powered tools for professional networking, email management, and a resale platform for brands and retailers. Its mobile email product uses artificial intelligence to reduce inbox overload, surface relationship insights, provide smart notifications, and snooze messages, integrating with existing email services and supporting iOS and Android. In parallel, Trove operates a resale platform that helps brands launch, manage, and scale resale programs, with storefront design, photography, authentication, cleaning and repair, returns processing, non-new inventory management, site building, Shopify integration, and analytics, plus in-store and digital trade-ins and peer-to-peer features. By combining AI-driven relationship mapping with a scalable resale ecosystem, Trove enables brands to deepen engagement, optimize profit, and reach new customers, and holds certification as a B Corporation for its sustainability-focused approach.

Strata Oncology, Inc. is a precision oncology company focused on enhancing cancer care by facilitating access to precision medicine clinical trials and expediting drug approval processes. Based in Ann Arbor, Michigan, the company develops a comprehensive precision oncology platform that supports routine testing and efficient use of molecular data. Strata's offerings include The Strata Trial, a genomic testing program for systematic precision oncology implementation, and StrataNGS, a targeted assay for sequencing DNA and RNA from biopsies. Additionally, StrataPOINT integrates electronic medical record histories with molecular profiling to ensure eligible patients are tested and considered for trial enrollment. The company features a portfolio of pharma-sponsored therapeutic protocols, known as Strata Partnered Trials, aligned to specific biomarkers. Strata also operates The Strata Lab, a cancer sequencing facility, and maintains the Strata Precision Oncology Network, a collaborative entity aimed at promoting precision medicine initiatives. Formerly known as Strata Oncology Research, Inc., the company rebranded in 2016 and has been incorporated since 2015.

Lucid Motors, established in 2007, specializes in manufacturing electric vehicles (EVs). Headquartered in Menlo Park, California, with a production facility in Casa Grande, Arizona, the company aims to create innovative EVs that transcend conventional limitations of space, performance, and intelligence. Lucid Motors has strategic partnerships with battery cell suppliers Samsung SDI and LG Chem to support its EV production.

Hyzon Motors Inc is a manufacturer of hydrogen fuel cell-powered commercial vehicles, specializing in heavy-duty trucks, medium-duty trucks, and buses, including city and coach models. Founded in 2020 and headquartered in Honeoye Falls, New York, the company operates on a global scale, servicing markets in North America, Europe, China, and Australasia. Hyzon is committed to addressing the demand for zero-emission vehicles by integrating its advanced fuel cell and electric propulsion technologies into established vehicle platforms. In addition to vehicle manufacturing, the company is actively involved in developing a clean hydrogen supply ecosystem, collaborating with partners across the entire value chain, from feedstocks and production to dispensing and financing. This approach positions Hyzon to potentially expand its offerings to include light-duty commercial vehicles in the future.

Payoneer is a financial technology company that operates a cross-border payments platform enabling small and medium-sized businesses to transact globally. The platform provides a Global Payment Service offering access to receiving accounts in the United States, the European Union, and Japan, allowing users to receive local bank transfers into their Payoneer account. It also supports mass payout capabilities from integrated partners across freelance, vacation rental, e-commerce, stock photography, and affiliate networks, enabling funds to be deposited directly into users' bank accounts. The service facilitates international transfers for companies and marketplaces in India and across multiple currencies. Payoneer serves freelancers, e-commerce businesses, and online advertisers, helping them grow and operate in the digital economy. Founded in 2005 and based in New York, the company focuses on connecting businesses to international markets and providing a secure, reliable cross-border payments experience.

Perella Weinberg Partners is an independent, privately owned financial services firm that provides corporate advisory and asset management services to clients worldwide. The firm is organized into two business units: corporate advisory and asset management. It serves institutional investors and other clients across industries, offering mergers and acquisitions advisory, financial restructuring, capital structure advisory, private capital raising, pension matters, and strategic and government advisory, alongside investment vehicles for institutional clients. The firm draws on experienced professionals recruited from leading global financial institutions and conducts in house research to inform its advisory and investment activities. Headquartered in New York City, Perella Weinberg Partners operates globally through a network of offices.

Lendbuzz, Inc. is a Boston-based company that operates an innovative car financing platform aimed at individuals with limited or no credit history, such as international students, foreign professionals, and expatriates. Founded in 2015, Lendbuzz uses machine learning algorithms and proprietary technology to assess the creditworthiness of consumers who are typically underserved by traditional financial institutions. By evaluating background information, including employment and educational history, the platform provides tailored car loans and financing solutions with favorable terms and low-interest rates. Lendbuzz partners with auto dealerships to enhance their offerings, allowing them to serve a more diverse clientele and close additional business opportunities. The company emphasizes a streamlined documentation process, making it easier for clients to access and manage their loans.

Faire is a two-sided marketplace connecting local retail stores with unique wholesale merchandise from brands and makers. It offers retailers tools for data insights, financial terms, and logistics support to compete with larger competitors. Faire's platform simplifies wholesale buying and selling processes, offering net 60 payment terms and free returns.

Latch is a technology company that provides an integrated smart building platform for multifamily properties. It deploys hardware and software to digitize building and unit access and in-unit device control, delivered via a cloud-based software-as-a-service platform known as the Latch Platform. The company offers products including cameras, locks, interconnects, and smart sensors that connect with the platform to manage access and building operations for owners, residents, guests, couriers, and service providers.

NiKang Therapeutics, Inc. is a biotechnology company established in 2017 and headquartered in Wilmington, Delaware. The company specializes in the discovery and development of small molecule oncology medicines aimed at addressing unmet medical needs in cancer treatment. Utilizing a discovery approach informed by target structure biology, NiKang employs structure-based drug design to facilitate the rapid and efficient development of proprietary drug candidates. This methodology enables the company to create innovative therapies with desirable pharmacological properties, ultimately aimed at improving the lives of patients through enhanced treatment options.

SnapDocs, Inc. is a real estate technology company that specializes in digital mortgage closings. Founded in 2013 and headquartered in San Francisco, California, SnapDocs provides a platform that connects lenders, title companies, notary signing agents, and homebuyers, facilitating a streamlined closing process. The platform automates interactions among these participants, ensuring efficiency, accuracy, and consumer satisfaction. It offers features such as performance metrics for mobile notary signing agents, customizable workflows for lenders and real estate professionals, and early access to closing packages for homebuyers. By leveraging advanced automation and patented technology, SnapDocs enhances the closing experience, enabling clients to save time and reduce costs while maintaining compliance. The company's focus on improving both borrower experience and business outcomes positions it as a leading solution in the mortgage closing industry.

Nuvalent is a biotechnology company focused on developing targeted therapies for clinically proven kinase targets in cancer. Leveraging expertise in structure-based design, Nuvalent creates innovative small molecules with exquisite target selectivity to overcome resistance and minimize adverse events.

Oxford Nanopore Technologies Limited is a biotechnology company specializing in the development and commercialization of nanopore-based sequencing technology for the analysis of DNA, RNA, proteins, and small molecules. Its innovative product lineup includes the portable MinION device, the benchtop PromethION, and the GridION system, all of which enable real-time data streaming and scalable sequencing for a variety of applications in scientific research, personalized medicine, environmental monitoring, and agriculture. The Flongle offers smaller, on-demand sequencing solutions, catering to users requiring rapid insights. Operating in over 80 countries, Oxford Nanopore's technology is designed for accessibility and ease of use, featuring straightforward library preparation and automated solutions. The company maintains a robust patent portfolio, supporting its ongoing research and development in both biological and solid-state nanopore technologies. Founded in 2005 and based in Oxford, United Kingdom, Oxford Nanopore Technologies also has offices in multiple countries, including the United States, China, and Germany.

Boundless Bio develops innovative cancer therapeutics focused on understanding and treating previously untreatable cancers. It specializes in targeting extrachromosomal DNA (ecDNA) biology, a key driver of aggressive cancers.

Scale AI develops a platform that provides training and validation data for artificial intelligence applications. Its products include advanced annotation tools for images, videos, text, documents, and 3D sensor data, serving sectors such as autonomous vehicles, retail, conversational AI, robotics, AR/VR, and document processing.

Patreon operates a platform that connects content creators and artists with their patrons. It enables creators to fund their work through recurring payments from patrons, who gain access to exclusive content and benefits in return.

Entrada Therapeutics, Inc. is a clinical-stage biotechnology company based in Boston, Massachusetts, focused on treating diseases through the intracellular delivery of biologics. Founded in 2016, the company has developed innovative technologies that facilitate the efficient delivery of proteins, peptides, and nucleic acids, targeting intracellular sites that have traditionally been difficult to access. Entrada's approach includes Intracellular Enzyme Replacement Therapy (IC-ERT) and Endosomal Escape Vehicle (EEV) therapeutics, which aim to improve the therapeutic index by enabling the delivery of a wide range of therapeutics across various organs and tissues. The company's pipeline addresses conditions related to neuromuscular diseases and expands into additional therapeutic areas, positioning Entrada at the forefront of advancing treatment options for patients with devastating illnesses.

Founded in 2018, Scribe Therapeutics specializes in engineering and developing in vivo therapies based on CRISPR technology to rewrite and repair genetic disorders. Its proprietary platform, X-Editing (XE), enables greater efficacy, specificity, and deliverability compared to existing CRISPR technologies.

Arrival Communications, established in 1991 and headquartered in Bakersfield, California, specializes in providing voice and data communication services to businesses in Central California. The company offers a range of services, including local and long-distance voice services, dedicated networks, integrated solutions, and data services such as high-speed internet access and mobile wireless services. Notably, Arrival Communications is building a facilities-based network to serve businesses in smaller cities throughout the Western United States, expanding its reach and capabilities.

Zenas BioPharma is a clinical-stage biopharmaceutical company focused on developing immune-based therapies for autoimmune and immune-mediated diseases. Based in Florida, United States, the company advances biologic programs and aims to modulate B cell–driven pathology. Its lead product candidate, obexelimab, is a bifunctional monoclonal antibody designed to bind both CD19 and FcγRIIb on B cells, thereby inhibiting harmful immune activity without depleting B cells.

Ventyx Biosciences is a clinical-stage biopharmaceutical company focused on developing novel therapies for patients with inflammatory diseases and autoimmune disorders. Its pipeline includes VTX958, an oral, selective TYK2 inhibitor in Phase 1 trials for various autoimmune diseases.

Butterfly Network is a medical technology company developing handheld ultrasound systems that aim to democratize imaging and expand access to care. Its flagship device, a single-probe handheld system powered by Ultrasound-on-Chip semiconductor technology, enables whole-body diagnostic imaging with cloud-connected software and a mobile application, allowing clinicians to acquire, store, and analyze ultrasound data in real time. The platform supports workflow integration for hospitals and outpatient settings, and can image vascular, cardiac, abdominal, urological, fetal, gynecological, and musculoskeletal regions. The company envisions improving early detection and remote management of health conditions by enabling pocket-sized imaging capability and scalable ultrasound programs across healthcare facilities. Butterfly Network was founded with a mission to advance global health equity by increasing ultrasound access worldwide. The technology combines a compact hardware device with software to streamline acquisition, interpretation, and sharing of ultrasound information in clinical workflows.

Gemini Therapeutics, Inc. is a precision medicine company based in Cambridge, Massachusetts, founded in 2015. The company specializes in developing new therapies for patients experiencing dry age-related macular degeneration (AMD) and related rare genetic diseases. Gemini Therapeutics focuses on genetically defined conditions, creating therapeutic candidates that address molecular abnormalities in patients with significant clinical needs. Their diverse pipeline encompasses monoclonal antibodies, recombinant proteins, and gene therapies, positioning the company to potentially introduce first-in-class therapeutics. The development of these innovative treatment options is supported by collaborations with leading life science investors and academic institutions worldwide, reflecting a commitment to advancing medical care for individuals suffering from these conditions.

Design Therapeutics, Inc. is a clinical-stage biotechnology company headquartered in Solana Beach, California, focused on developing innovative therapies for serious degenerative disorders caused by nucleotide repeat expansions. The company specializes in a novel class of small-molecule gene-targeted chimera therapeutics known as GeneTACTM molecules, which aim to modify disease progression by addressing the root causes of these conditions. Its lead program targets Friedreich’s ataxia, while additional efforts are directed toward conditions such as Fuchs endothelial corneal dystrophy and other degenerative diseases like Fragile X syndrome and myotonic dystrophy. Since its incorporation in 2017, Design Therapeutics has been dedicated to advancing its therapeutic candidates to potentially transform treatment options for patients suffering from these inherited disorders.

Verve Therapeutics is a biotechnology company developing genetic medicines for cardiovascular disease, aiming to transform treatment from chronic management to single-course gene editing therapies. It leverages human genetics analysis and gene-editing technology, with expertise in cardiovascular medicine, human genetics, gene editing, delivery technologies, drug development, and commercialization.

Affinivax, Inc. is a biotechnology company based in Lexington, Massachusetts, specializing in the development of vaccines using its innovative Multiple Antigen Presenting System (MAPS) technology. Founded in 2014, the company aims to enhance the protection against a range of infectious diseases that affect both children and adults globally. MAPS technology allows for the effective binding of protective polysaccharides and proteins within a single vaccine, inducing robust immune responses. Affinivax is advancing vaccine programs targeting significant pathogens, including Streptococcus pneumoniae, which contributes to considerable morbidity and mortality worldwide. The company leverages insights from leading experts in infectious diseases and has secured exclusive intellectual property rights related to its MAPS platform from Boston Children’s Hospital, with notable backing from the Bill & Melinda Gates Foundation.

Founded in 2020 and headquartered in Boston, Massachusetts, Scorpion Therapeutics is a clinical-stage biotechnology company specializing in precision oncology. It develops targeted small-molecule drugs to treat cancer by focusing on three areas: therapies against known oncogenes, agents for currently undruggable targets, and drugs for new targets.

Porch.com, Inc. operates an online platform designed to connect homeowners with local home repair services and facilitate the arrangement of installation services for products purchased through e-commerce channels. Founded in 2011 and based in Seattle, Washington, the company provides a range of services to enhance the homeownership experience. Its offerings include a moving concierge service that assists homebuyers in navigating essential services such as insurance, security, and internet services, thereby streamlining the moving process. Furthermore, Porch provides software solutions tailored for home service providers, including tools for inspections and mortgage services, supporting various aspects of home management and improvement. The company also maintains a strategic partnership with Cinch Home Services Inc., enhancing its service offerings in the home services sector.

Edgewise Therapeutics is a clinical-stage biopharmaceutical company focused on developing innovative treatments for severe, rare muscle disorders with significant unmet medical need. It employs a holistic drug discovery approach targeting the muscle as an organ, utilizing its proprietary platform to identify precision medicines regulating key proteins in muscle tissue.

Scopely, Inc., established in 2011 and headquartered in Culver City, California, is a leading developer of mobile and tablet touchscreen-based games for casual and core gamers worldwide. The company creates, publishes, and live-operates immersive games, including popular franchises like "Star Trek™ Fleet Command," "MARVEL Strike Force," and "Stumble Guys." Scopely offers a range of services, such as game design, live operations, marketing, analytics, and advertising, empowering a consumer-directed gaming experience. With a diverse portfolio and a proprietary technology platform, Playgami™, Scopely has operations in multiple markets across Asia-Pacific, EMEA, and North America, employing a world-class team to create long-lasting game experiences.

Lordstown Motors is an automotive company specializing in the development and manufacture of light-duty electric trucks, primarily for fleet customers.

Nuvation Bio is a global biopharmaceutical company dedicated to developing innovative therapies for oncology, focusing on patients with difficult-to-treat cancers where conventional treatments have proven ineffective.

Novellus is a biotechnology company working to develop engineered cellular medicines. The company uses its non-immunogenic mRNA molecules to reprogram and gene-edit cells safely, and with high efficiency. They engineer precision medicines for patient segments and select from its technology toolbox for in vivo, ex vivo, allogeneic and autologous delivery. Novellus platform enables the high-level expression of gene-editing and cell-reprogramming proteins for high-specificity gene repair and both autologous and allogeneic cell therapies. The company is advancing its lead program, a breakthrough therapy for a rare dermatologic disease, through pre-clinical studies. Novellus was founded in 2015 and is headquartered in Cambridge, Massachusetts, United States.

Affirm is a financial technology company that offers consumer installment loans at the point of sale through its Buy with Affirm platform. Shoppers can select Affirm at checkout and pay for purchases in fixed monthly installments with real-time decisioning and upfront, transparent terms, avoiding hidden fees. The company provides a digital and mobile‑first platform that includes a point‑of‑sale payment solution for merchants and a consumer app, and it partners with thousands of merchants across categories such as home, travel, electronics, apparel, and beauty. Revenue comes from merchant networks and related services, including virtual card networks, with the majority of business generated in the United States, and ongoing activity in Canada and other regions. Founded in 2012 and headquartered in San Francisco with an additional office in Chicago, Affirm aims to offer an accessible alternative to traditional credit that improves budgeting and financial clarity for consumers.

ESCAPE Bio is a clinical-stage biopharmaceutical company focused on discovering and developing small molecule therapies for genetically defined subpopulations affected by neurodegenerative diseases. Founded in 2015 and based in South San Francisco, California, the company aims to improve the lives of patients suffering from conditions such as Alzheimer's disease, Parkinson's disease, and sphingolipid storage disorders. ESCAPE Bio's pipeline includes innovative candidates like ESB1609, a small molecule S1P5 receptor agonist targeting CNS lysosomal storage disorders, and ESB5070, a kinase inhibitor specifically designed for Parkinson's patients with the LRRK2 G2019S variant. Additionally, the company is developing a program aimed at addressing the needs of Alzheimer's patients who carry the ApoE4 risk allele. Through its precision-targeted approach, ESCAPE Bio seeks to provide effective treatment options for individuals with these complex genetic profiles.

Skillz is a mobile games platform focused on enhancing competition through engaging gameplay. It enables game developers to create successful franchises by facilitating social competition within their games. Utilizing patented technology, Skillz hosts billions of casual gaming tournaments, attracting millions of players globally. As a leader in skill-based mobile gaming, the company offers a variety of games, including Dominoes Gold, Blackout Bingo, 21 Blitz, and Solitaire Cube. Skillz operates primarily through its eSports gaming platform, which allows developers to monetize their content via multiplayer competitions. The company generates most of its revenue from the United States, with additional income from international markets such as Israel, China, and Malta. Skillz has received recognition for its workplace culture and innovation in the technology sector.

Patreon operates a platform that connects content creators and artists with their patrons. It enables creators to fund their work through recurring payments from patrons, who gain access to exclusive content and benefits in return.

Synthego is a biotechnology company specializing in genome engineering. It offers integrated hardware, software, bioinformatics, chemistries, and molecular biology platforms to advance basic research and therapeutic development. Its products include engineered cells, CRISPR kits, and bioinformatics tools for gene knockout, target validation, and disease modeling. Synthego serves scientists globally, with sales through distributors in multiple countries and online.

Dyne Therapeutics is a clinical-stage biotechnology company developing therapies for genetically driven neuromuscular diseases. It aims to deliver disease-modifying therapeutics to skeletal, cardiac, and smooth muscle, addressing conditions such as muscular dystrophies and other muscle disorders. The company uses the FORCE platform to create targeted therapeutics with payloads designed to address the disease gene, connected via a linker to an antigen-binding fragment, enabling delivery to muscle tissue and the central nervous system. Its pipeline includes DYNE-101, DYNE-251, DYNE-302, and DYNE-401. Headquartered in Waltham, Massachusetts.

PMV Pharmaceuticals, Inc. is a precision oncology company focused on the discovery and development of small molecule therapies targeting p53 mutations in cancer. Its lead candidate, PC14586, aims to correct and restore the function of the p53 protein, which is critical in regulating cell growth and preventing tumor formation. In addition to PC14586, the company is developing therapies for various p53 hotspot mutations, including the R273H mutation. Founded in 2013 and headquartered in Cranbury, New Jersey, PMV Pharmaceuticals leverages extensive expertise in p53 biology to advance its innovative treatment options for cancer patients.

VelosBio, Inc. is a clinical-stage biopharmaceutical company based in San Diego, California, focused on developing innovative antibody-drug conjugates (ADCs) to treat various hematological cancers and solid tumors. Established in 2017, the company specializes in therapies that target receptor tyrosine kinase-like orphan receptor 1 (ROR1), a protein present on many cancerous cells but absent in normal tissues, making it a promising target for cancer treatment. VelosBio's lead product, VLS-101, is an ROR1-directed ADC designed for patients with both hematologic and solid tumor malignancies. The company's approach aims to provide novel targeted therapies that can be utilized as monotherapy or in combination with other treatments across a wide array of cancer types.

Goldfinch Bio, Inc. is a clinical-stage biotechnology company based in Cambridge, Massachusetts, dedicated to discovering and developing precision therapies for patients with kidney diseases. The company focuses on conditions such as focal segmental glomerulosclerosis, diabetic nephropathy, and polycystic kidney disease. Key product candidates include GFB-887, a selective inhibitor of the TRPC5 channel, and GFB-024, a cannabinoid receptor 1 inverse agonist. Goldfinch Bio integrates advancements in kidney genetics and biology through its Kidney Genome Atlas, a genomic registry that aids in identifying new disease targets and biomarkers. Additionally, the company employs stem cell science to create human organoid models, which facilitate the validation of novel therapeutic targets. Goldfinch Bio has established a strategic collaboration with Gilead Sciences to further enhance its research and development efforts. Founded in 2016, Goldfinch Bio aims to transform the treatment landscape for progressive kidney disease.

Prove specializes in smartphone-based identity verification, offering phone-centric solutions that enable businesses to securely acquire new consumers and engage with existing ones. Its solutions reduce friction, enhance security, and protect consumer privacy.

Verve Therapeutics is a biotechnology company developing genetic medicines for cardiovascular disease, aiming to transform treatment from chronic management to single-course gene editing therapies. It leverages human genetics analysis and gene-editing technology, with expertise in cardiovascular medicine, human genetics, gene editing, delivery technologies, drug development, and commercialization.

Nurix Therapeutics is a biopharmaceutical company focused on discovering, developing, and commercializing oral small-molecule therapies that modulate cellular protein levels to treat cancer and immune disorders. It operates DELigase, an integrated discovery platform that targets E3 ligases to alter protein abundance within cells. The company's product pipeline includes targeted protein degraders such as NX-2127, an oral Bruton's tyrosine kinase degrader for relapsed or refractory B-cell malignancies, and NX-1607, an oral Casitas B-lineage lymphoma proto-oncogene-B inhibitor for immuno-oncology indications; these are in preclinical stages. Nurix also explores inhibitors of CBL-B, an E3 ligase that regulates T cell activation. The company collaborates with major industry partners, including Gilead Sciences and Sanofi, and was founded in 2009 and is headquartered in San Francisco.

Kymera Therapeutics is a biotechnology company focused on targeted protein degradation. It employs a proprietary predictive modeling platform to discover novel small molecule therapeutics that selectively degrade disease-causing proteins.

Generation Bio is a genetic medicines company developing durable, redosable treatments for patients with rare and prevalent diseases. Its non-viral platform combines closed-ended DNA, cell-targeted lipid nanoparticles, and scalable manufacturing processes to deliver large and multiple genes across various tissues.

Forma Therapeutics, headquartered in Watertown, Massachusetts, is a clinical-stage biopharmaceutical company focused on developing and commercializing innovative therapeutics for rare hematologic diseases and various cancers. The company is advancing several key product candidates, including FT-4202, currently in Phase 1 trials for sickle cell disease and other hemoglobinopathies, and FT-7051, targeting metastatic castration-resistant prostate cancer. Additionally, Forma is developing FT-2102, a selective small molecule designed to inhibit mutated IDH1 enzymes, which is being evaluated in Phase 2 trials for relapsed/refractory acute myeloid leukemia and in exploratory trials for glioma. Other candidates include FT-4101 and FT-8225, selective inhibitors of fatty acid synthase. The firm integrates advanced drug discovery technologies with deep oncology expertise to address challenging targets, contributing to a robust pipeline aimed at transforming patient outcomes in oncology.

Black Diamond Therapeutics discovers and develops small molecule therapies for precision oncology. It focuses on allosteric mutations in kinases related to cancer, with a lead product candidate targeting non-canonical ErbB kinase mutations.

Impulse Dynamics N.V. is a medical device company that specializes in developing innovative electrical therapies for chronic heart failure. Founded in 1996 and headquartered in Willemstad, Curacao, the company also maintains offices in New York and Hong Kong, with product development centers located in New Jersey and Israel. Its primary offering, the CCM® therapy, utilizes cardiac contractility modulation technology to deliver non-excitatory electrical impulses to the heart, enhancing its contraction and improving blood flow to the body. This minimally invasive treatment option addresses the needs of heart failure patients who have limited alternatives. Impulse Dynamics conducts clinical trials to assess the safety and efficacy of its therapies and collaborates with universities and hospitals for ongoing research and development.

ACV Auctions, Inc. is a wholesale automotive auction company headquartered in Buffalo, New York, founded in 2014. It operates a mobile platform that facilitates online auctions for used-car dealers, allowing them to view, bid on, and purchase car inventory directly from other dealers. The platform provides a digital marketplace that streamlines the buying and selling process, offering real-time alerts for available vehicles and enabling live auction participation. Additionally, ACV Auctions offers a pricing application tailored for franchise dealers, enhancing the auction experience and providing transparent and accurate vehicle information to users.

Omada Health is a digital healthcare company that offers personalized programs to manage chronic conditions such as prediabetes, diabetes, hypertension, musculoskeletal issues, and behavioral health. It combines professional coaching, connected devices, real-time data, and personalized feedback to deliver clinically meaningful results.

Satsuma Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company focused on developing innovative treatments for migraine. The company's lead product candidate, STS101, is a drug-device combination that incorporates a proprietary dry-powder formulation of dihydroergotamine mesylate. Designed for self-administration, STS101 utilizes a pre-filled, single-use nasal delivery device, enhancing patient convenience and accessibility. The product is currently undergoing Phase III clinical trials, marking a significant step in its development. Founded in 2016, Satsuma is headquartered in South San Francisco, California.